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Cyclocreatine treatment 
ameliorates the cognitive, autistic 
and epileptic phenotype in a mouse 
model of Creatine Transporter 
Deficiency
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Creatine Transporter Deficiency (CTD) is an inborn error of metabolism presenting with intellectual 
disability, behavioral disturbances and epilepsy. There is currently no cure for this disorder. Here, we 
employed novel biomarkers for monitoring brain function, together with well‑established behavioral 
readouts for CTD mice, to longitudinally study the therapeutic efficacy of cyclocreatine (cCr) at 
the preclinical level. Our results show that cCr treatment is able to partially correct hemodynamic 
responses and EEG abnormalities, improve cognitive deficits, revert autistic‑like behaviors and protect 
against seizures. This study provides encouraging data to support the potential therapeutic benefit of 
cyclocreatine or other chemically modified lipophilic analogs of Cr.
Creatine Transporter Deficiency (CTD) is an inborn error of metabolism with X-linked inheritance pattern 
(OMIM #300352). The clinical presentation of CTD includes brain creatine (Cr) shortage, mild to severe intel-
lectual disability, behavioral disturbances or autistic-like features and  epilepsy1, and typically arises between 
birth and 6 years of  age2.
Although rare, CTD represents a major issue in health-care, causing chronic illness with a considerable impact 
on the everyday quality of life of patients and caregivers. Previous attempts to rescue creatine (Cr) content in the 
brain and attenuate the symptoms of CTD children by exploiting nutritional supplements based on Cr alone and/
or administered together with its synthesis precursors have been of very limited  success3–8. Thus, there are cur-
rently no satisfactory treatments for this disorder, and the mainstay of care is a palliative approach for managing 
seizures and behavioral problems. In recent times, knock-out murine models for the creatine transporter (CrT) 
gene showing high face validity and the discovery of novel quantitative biomarkers have led to a significant leap 
for the development of potential therapeutic  agents9–15.
Here, we performed a randomized, blinded, placebo-controlled, preclinical study to explore the therapeutic 
efficacy of a chronic (24 week) oral daily treatment with cyclocreatine (cCr) at three different dose levels in CrT 
knock-out  (CrT−/y) mice. It has been reported that lipophilic analogs and other derivatives of Cr can enter cells 
independently of CrT and could represent a promising approach for CTD  treatment10,16–19. In particular, cCr is 
a nearly planar Cr analog that can be phospho/dephosphorylated by Cr kinase, thus mimicking the metabolic 
function of  Cr10,20,21. However, the evaluation of cCr and other treatment options in CTD has been limited to 
biochemical measurements, behavioral outcomes and in vitro assays of neuronal function. We combined func-
tional biomarker assessment with well-established behavioral readouts for  CTD11,15 to monitor brain function 
of  CrT−/y mice in response to pharmacological intervention with cCr.
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Results
cCr was administered orally once daily at three different doses (high dose, H: 140 mg/kg, medium dose, M: 
46 mg/kg, low dose, L: 14 mg/kg) to  CrT−/y mice and wild-type littermates starting at postnatal day (PND) 21. 
We longitudinally evaluated the therapeutic efficacy of cCr treatment in the same animals, using intrinsic opti-
cal signal (IOS) imaging, a panel of behavioral test (Y maze, Morris water maze, rotarod, self-grooming) and 
video-EEG recordings (Fig. 1a).
cCr treatment improves cortical hemodynamics in  CrT−/y mice. Since we recently reported that 
hemodynamic responses are altered in the visual cortex  CrT−/y mice with no impairment of visually-evoked 
potentials and that hemodynamic measurements are a reliable biomarker of brain function in  CTD15, we first 
explored the therapeutic efficacy of cyclocreatine (cCr) using IOS imaging (Fig.  1a). We found a dose- and 
age-dependent effect on hemodynamic responses in  CrT−/y mice administered cCr. The altered IOS amplitude 
observed in  CrT−/y mice was significantly attenuated in  CrT−/y mice treated with the high dose of cCr (H-CrT−/y) 
at every time point tested. The medium dose (M-CrT−/y) ameliorated IOS signals at PND110 and PND180, and 
the low dose (L-CrT−/y) was effective only at PND180 (Fig. 1b,c, Fig. S1). No difference was detected between 
untreated animals  (CrT−/y) and vehicle-treated mice (V-CrT−/y, Fig. 1b,c, Fig. S1). These data suggest that cCr 
delivery is able to circumvent, at least partially, the metabolic impairment caused by Cr depletion, leading to the 
reversion of the neurovascular phenotype characterizing  CrT−/y mice.
cCr reduces deterioration of cognitive functions in  CrT−/y mice. After each IOS session, mice were 
subjected to serial neurobehavioral assessments of cognitive and psychomotor functions (Fig. 1a). We previ-
ously reported that  CrT−/y animals exhibit a general cognitive impairment across different learning and memory 
 tasks11. The performance in the Y maze revealed a moderate but statistically significant increase in the spontane-
ous alternation for H-CrT−/y and M-CrT−/y mice at PND44, indicating a cognitive improvement in these groups 
of animals. No beneficial effects of treatment were detected at PND114, while all three cCr doses comparably 
improved working memory at PND184 (Fig. 2a). V-CrT−/y showed an alternation rate comparable to untreated 
animals (Fig. 2a). We further assessed memory abilities using the Morris Water Maze (MWM) at PND116 and 
PND186. While no positive effects of cCr administration were detected at PND116 (Fig. S2), M-CrT−/y mice 
Figure 1.  cCr treatment improves hemodynamic responses in  CrT−/y mice. (A) Schematic diagram of the 
experimental design. We employed IOS imaging, behavioral assessment (Y maze, Morris water maze, rotarod 
and self-grooming) and video-EEG recordings to evaluate the therapeutic efficacy of longitudinal treatment 
with cCr at three different doses (high dose, H: 140 mg/kg, medium dose, M: 46 mg/kg, low dose, L: 14 mg/
kg). Untreated mice  (CrT−/y) and animals administered with placebo (only chocolate milk, V-CrT−/y) were used 
as controls. List of abbreviations—B: birth; TS: treatment starts; IOS: intrinsic optical signal; YM: Y maze; R: 
rotarod; MWM: Morris Water Maze; SG: self-grooming; PND: postnatal day. (B) Representative IOS response 
images collected at different ages (PND40, PND110 and PND180) in  CrT−/y, V-CrT−/y, H-CrT−/y, M-CrT−/y and 
L-CrT−/y mice (n = 15 for each group at each time point, except n = 17 each for  CrT−/y, H-CrT−/y and M-CrT−/y 
mice at PND180). (C) Mean amplitude of visually evoked IOS responses measured after 20 (PND40), 90 
(PND110) and 160 (PND180) days of cCr delivery. Two-way ANOVA revealed a significant effect of treatment 
(p < 0.001) and post-hoc Dunnett’s multiple comparisons test showed an amelioration of hemodynamic 
responses in H-CrT−/y mice at every time point tested (p < 0.01 at PND40, p < 0.001 at PND110 and PND180), 
whereas IOS signals were attenuated at PND110 (p < 0.001) and PND180 (p < 0.01) in M-CrT−/y animals, and 
only at PND180 (p < 0.05) in L-CrT−/y mice. No difference was present between untreated  CrT−/y animals and 
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were significantly stronger learners compared to age-matched untreated  CrT−/y animals at PND186, with a 
shorter distance to locate the platform during the training phase (Fig. 2b). The lack of impact of cCr treatment 
on swimming velocity (Fig. 2c) attributes this improvement in distance to learning, rather than to any impact 
of cCr on skeletal muscle. Although there was no unilateral preference for the target quadrant in the probe 
trial, H-CrT−/y and M-CrT−/y animals mostly explored the target quadrant and the adjacent one, suggesting the 
presence of a memory trace (Fig. 2d). No difference was observed between untreated and vehicle-treated  CrT−/y 
Figure 2.  cCr treatment attenuates cognitive deterioration in  CrT−/y mice. (A) Histograms depict the 
spontaneous alteration rate in the Y maze for the different experimental groups at PND44, PND114 and 
PND184 (n = 15 for each group at each time point, except n = 17 each for  CrT−/y, H-CrT−/y and M-CrT−/y mice at 
PND180). The performance of H-CrT−/y and M-CrT−/y animals was statistically higher than  CrT−/y littermates 
at PND44 (Two-way ANOVA, effect of treatment p < 0.001, post-hoc Dunnett’s multiple comparisons test, 
p < 0.05) and PND184 (p < 0.01 for H-CrT−/y group, p < 0.001 for M-CrT−/y mice); L-CrT−/y showed a slightly 
improved spontaneous alternation only at PND184 (p < 0.01). No difference emerged between  CrT−/y animals 
and V-CrT−/y mice at every age tested (p = 0.767 at PND44, p = 0.999 at PND114, p = 0.112 at PND184). The inset 
depicts a schematic diagram of the Y maze apparatus. (B–D) MWM at PND186 (n = 15 for each group, except 
n = 17 each for  CrT−/y, H-CrT−/y and M-CrT−/y mice). The mean swimming path covered prior to locate the 
submerged platform on the last three days of training (B) was statistically shorter in M-CrT−/y mice (One-way 
ANOVA, p < 0.05, post-hoc Dunnett’s multiple comparisons test, p < 0.05). The inset shows a representative 
example of swimming path during the training phase. Mean swimming speed (C) was unaffected by cCr 
treatment (One-way ANOVA, p = 0.774). Open symbols represent single data values; black lines indicate median 
with 95% CI. (D) Probe trial. A Two-Way RM ANOVA followed by Dunnett’s multiple comparisons revealed 
that while  CrT−/y animals did not show any exploration preference, H-CrT−/y mice spent significantly more 
time in the T quadrant than in the opposite (O, p < 0.01) and in the left (L, p < 0.01) quadrants. No difference 
was present between the time in the T and the right (R) quadrant (p = 0.968). Moreover, a significant difference 
was detected between the time in R quadrant and O (p < 0.05) and L (p < 0.05) quadrants. M-CrT−/y mice spent 
significantly more time in the T quadrant than in the L quadrant (p < 0.01). No effect of the low cCr dose or 
vehicle treatment was detected. The inset shows a representative example of swimming path during the probe 
phase. * p < 0.05, # p < 0.01, § p < 0.001. Open symbols represent single data values; histograms and lines indicate 
median with 95% CI.
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animals (Fig. 2b–d). Altogether, these results suggest that cCr has a partial effect in restoring the learning and 
memory functions deteriorated in CrT deficiency conditions. On the other hand, cCr treatment did not result 
in any change of body weight (Fig. S3), substantiating the lack of impact of cCr treatment on skeletal muscle 
observed in the MWM.
Repetitive and stereotyped behavior of  CrT−/y mice is reverted following cCr treatment. We 
formerly outlined that, despite the lack of differences in sociability, stereotyped behaviors in the rotarod and 
self-grooming test seem to be amplified in  CrT−/y mice, demonstrating that the endophenotype of this mouse 
model includes autistic-like  features11,22–29. Here, we found that all three dose levels of cCr were effective in 
reducing the manifestation of stereotyped movements in the rotarod task at PND46, while at PND125 and 
PND195 only H-CrT−/y and M-CrT−/y animals displayed the same beneficial effect (Fig. 3a). These results were 
also corroborated by the measurement of self-grooming, with H-CrT−/y, M-CrT−/y and L-CrT−/y mice showing a 
drastic reduction in the time spent grooming themselves at PND195 (Fig. 3b). Thus, these data further support 
the beneficial activity of cCr at the level of the brain and suggest that cCr might have the ability to improve ASD-
related symptoms in CTD patients.
cCr protects against spontaneous epileptic phenotype and increases resistance to chemi‑
cally‑induced seizures. To assess the effects of cCr treatment on the epileptic phenotype recently observed 
in  CrT−/y  mice15, we used video-EEG recordings in freely-moving animals. The percentage of subjects experi-
encing spontaneous seizures at the clinical and electrographical level was significantly lower in H-CrT−/y and 
M-CrT−/y groups (Fig. 4a) and a significant increase of theta band power was detected in the brain of  CrT−/y 
mice treated with cCr compared to untreated  CrT−/y animals showing spontaneous seizures (Fig. 4b–g; Fig. S4). 
Spectral analysis also revealed a higher alpha frequency in H-CrT−/y mice during sleep (Fig. S4).
Based on these results, we assessed the response to KA challenge in H-CrT−/y and M-CrT−/y. Electrographical 
analysis and behavioral scoring revealed that H-CrT−/y animals display a more prolonged latency and a shorter 
duration of epileptiform bursts (Fig. 4h,j), although cCr treatment did not affect the frequency of evoked seizures 
(Fig. 4i). The distribution of seizure severity was also statistically different among the different groups, with 
H-CrT−/y and M-CrT−/y mice presenting a lower number of tonic–clonic events (Fig. 4k).
Taken together, these results suggest that cCr can protect against spontaneous seizures and shift epileptic 
susceptibility towards a milder phenotype.
cCr permeates the blood–brain barrier and gets into the brain. To assess the brain penetration of 
cCr, we monitored the pharmacokinetic profile in a group of animals following oral administration. We detected 
brain entry of cCr in all mice chronically treated with the drug, with higher levels of total cCr in H-CrT−/y mice 
than in M-CrT−/y and L-CrT−/y animals (Fig. 5). Moreover, longitudinal quantification of cCr at the three differ-
ent ages employed for behavioral and functional testing revealed that high-dose administration promptly leads 
to a rise in cCr concentration in the brain, with cCr reaching steady state levels following 23 days of dosing and 
remaining stable through the treatment period (Fig. 5).
Figure 3.  cCr treatment robustly decreases stereotyped behaviors in  CrT−/y mice. (A) A Two-way ANOVA 
highlighted a significant effect of treatment (p < 0.001) in the performance of  CrT−/y animals on the accelerating 
rotarod (n = 15 for each group at each time point, except n = 17 each for  CrT−/y, H-CrT−/y and M-CrT−/y mice at 
PND180). Post hoc Dunnett’s multiple comparison test showed that the fall latency of H-CrT−/y, M-CrT−/y and 
L-CrT−/y mice was significantly lower from that of  CrT−/y animals at PND46 (p < 0.001 for all groups), whereas 
only H-CrT−/y and M-CrT−/y mice exhibited an improved performance at PND125 (p < 0.05 for H-CrT−/y and 
p < 0.01 for M-CrT−/y) and PND195 (p < 0.001 for both groups). No difference was present between  CrT−/y 
animals and V-CrT−/y mice (p = 0.293 at PND46, p = 0.876 at PND125, p = 0.888 at PND195). Inset shows 
an illustration of the rotarod apparatus. (B) H-CrT−/y, M-CrT−/y and L-CrT−/y mice showed decreased self-
grooming behavior at PND195 (n = 15 for each group, except n = 17 each for  CrT−/y, H-CrT−/y and M-CrT−/y 
mice; One-way ANOVA, effect of treatment p < 0.001, post-hoc Dunnett’s multiple comparisons test, p < 0.001 
for H-CrT−/y and M-CrT−/y animals, p < 0.01 for L-CrT−/y mice). No effect of vehicle treatment was detected 
(p = 0.793). A schematic representation of self-grooming behavior is also shown. * p < 0.05, # p < 0.01, § p < 0.001. 
For all panels, open symbols represent single data values; black lines indicate median with 95% CI.
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No pathological changes are associated with cCr dosing. No cCr-related deaths or overt signs of 
toxicity were observed at any dose. We also investigated whether cCr dosing was accompanied by pathological 
changes in brain morphology. Amygdaloid body, basal nuclei/striatum, cerebellum, cerebral cortex, hippocam-
pus, hypothalamus, medulla oblongata, meninges, midbrain, olfactory bulb, pons, thalamus ventricular system, 
and white matter were evaluated in H-CrT−/y mice using a standard Hematoxylin and Eosin (H&E) staining. No 
variations in the neuroanatomical architecture were observed (Fig. S5).
Discussion
By using a wide battery of functional and behavioral assessment previously validated in this mouse model of 
 CTD11,15, we found that chronic cCr treatment was effective on different aspects of CTD, including cognitive 
dysfunction, autistic-like features and epilepsy. The outcome of this pharmacological approach has been previ-
ously evaluated in brain-specific CrT conditional knockout mice, reporting a beneficial effect for learning and 
Figure 4.  cCr treatment protects  CrT−/y mice against spontaneous and evoked epilepsy. (A) The percentage of 
animals experiencing spontaneous seizures at the clinical and electrographical level was significantly lower in 
H-CrT−/y (n = 15; Fisher’s exact test, p < 0.01) and M-CrT−/y mice (n = 12; p < 0.001) than in  CrT−/y group (n = 24). 
No beneficial effect was detected in L-CrT−/y animals (n = 9; p = 0.431). Untreated and V-CrT−/y mice were 
pooled together in the  CrT−/y group. (B–G) The comparison of power spectra of cortical EEG recordings with 
epileptic  CrT−/y mice  (CrT−/y -seizures, n = 7) revealed an increased power of 4–8 Hz theta frequency in cCr-
treated animals (One-way ANOVA, post-hoc Dunnett’s multiple comparisons test). Violin plots show individual 
values and the entire distribution of data. (H–K) Effect of KA treatment in  CrT−/y, H-CrT−/y and M-CrT-/ mice 
at behavioral and electrophysiological level. While no difference was present in the frequency of ictal events 
(I, One-way ANOVA, p = 0.897), H-CrT−/y mice displayed a longer latency (H, One-way ANOVA, effect of 
treatment p < 0.05, post-hoc Dunnett’s multiple comparisons test, p < 0.05) and a shorter duration (J, One-way 
ANOVA, effect of treatment p < 0.05, post-hoc Dunnett’s multiple comparisons test, p < 0.05) of epileptiform 
bursts compared to  CrT−/y animals. Open symbols represent single data values; black lines indicate median with 
95% CI. (K) Relative percentage of tonic, clonic and tonic–clonic seizures indicates that seizure severity is less 
pronounced in H-CrT−/y and M-CrT−/y animals at 10 mg/kg (χ2 test; p < 0.001). * p < 0.05, # p < 0.01, § p < 0.001.
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memory  deficits10. Consistent findings across multiple outcomes would help increase confidence in the robust-
ness and generalizability of preclinical results. The Kurosawa study, however, was mainly oriented in testing the 
effective ability of cCr to enter brain cells and to serve as substrate for Cr kinase, and a brain-specific rather than 
ubiquitous CrT knock-out model was used, representing a milder pathological endophenotype that seems to 
emerge quite late in  development14. Moreover, Kurosawa and colleagues probed only cognitive aspects of CTD, 
used aged animals (PND365), and treated for only a short duration (8 weeks) with a single dose level (allegedly 
280 mg/kg) of cCr ad libitum in drinking  water10.
Here, we designed the study to fulfill the best-practice guidelines for assessment in preclinical studies. This 
included incorporation of several key design aspects to ensure clinical translatability. The use of a mouse model 
where there is ubiquitous CrT loss aligns better with the genetics and the early onset of  CTD11. We verified that 
cCr reached the brain and the concentrations present at the end of chronic dosing duration were dose-responsive 
and consistent with those predicted by pharmacokinetic simulation of data previously obtained in a single oral 
dose biodistribution study (unpublished results, personal communication by Minh-Ha T. Do, Lumos Pharma). 
Moreover, we integrated robust statistical design with a priori computation of the sample size, minimization of 
genetic variability, random allocation of subjects to experimental groups, blinded assessment of readouts, longi-
tudinal quantification of multiple robust and reproducible outcome measures, and dose–response analyses with 
placebo controls to determine the minimum efficacious dose (MED) on different aspects of the CTD pathologi-
cal framework. Our results clearly indicate that the high (140 mg/kg) and the medium (46 mg/kg) doses have 
the stronger therapeutic effect in  CrT−/y mice and that the MED is potentially 46 mg/kg for cognitive defects 
and epileptic endophenotype, whereas 14 mg/kg may be sufficient to reduce autistic-like stereotyped behavior. 
This variability in the MED is likely to reflect distinct metabolic constraints of different brain processes, with 
the circuitry involved in the government of stereotyped movements possibly demanding less energy than those 
related to working and declarative memory.
Despite the progressive learning and memory deterioration reported in  CrT−/y  mice11, we found that cCr 
administration is still able to correct the cognitive phenotype at PND180, suggesting that cumulative beneficial 
effects on brain energy metabolism could result in a significant regression of early aging processes set in motion 
by Cr deficiency. This could be in part related to the time frame when dosing was initiated in this study. While it 
is challenging to relate developmental age of a rodent to that of a human, a PND21 mouse is roughly equivalent 
to a 1–3-year-old human child by multiple measures of nervous system  development30. Starting treatment at this 
age in the animal model coincides with the time point when CTD patients typically present clinically and our 
results indicate that early intervention may be critical. Accordingly, early treatment has been shown to be more 
beneficial in the other two Cr deficiency  syndromes31,32. The finding that cCr can impact disease progression also 
implies that long-term pharmacological intervention with cCr does not lead to the development of tolerance and 
these data highlight the relevance of patient compliance with chronic treatment protocols.
Importantly, our results show that cCr treatment is able to partially correct cortical hemodynamic responses 
measured through IOS imaging and EEG abnormalities caused by Cr  depletion15, demonstrating that these 
functional biomarkers enable tracking of disease progression and response to chronic treatment in the animal 
model. These data reinforce the concept that EEG and functional near-infrared spectroscopy (fNIRS, a non-
invasive method for assessing hemodynamics responses in  children33,34) might allow clinicians to optimize the 
follow-up of patients and to monitor the efficacy of potential therapeutic strategies on brain activity. Moreover, 
the study of EEG pattern could be predictive of the epileptic  phenotype15.
Figure 5.  Total brain cCr following cCr treatment. Concentrations of total cCr (summation of cCr and 
phospho-cCr) were measured in satellite H-CrT−/y mice at PND44, PND114 and PND184 (n = 7 for each 
time point), and in a subset of M-CrT−/y (n = 5) and L-CrT−/y (n = 4) mice from the efficacy study at PND195 
by LC–MS/MS. Circles represent single data values; black lines indicate medians with 95% CI. The dashed 
line represents median total creatine (creatine plus phospho-creatine) measured in brains of wild-type male 
C57BL/6J mice at PND28-35. One-way ANOVA, post-hoc Dunnett’s multiple comparisons test: # p ≤ 0.05 from 
L-CrT−/y, NS not statistically different from H-CrT−/y at PND 44.
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We did not report any detrimental effects of cCr treatment in this study, including no cCr-related deaths, 
pathological alterations in brain morphology, or exacerbation of the epileptic phenotype. In fact, we observed just 
the opposite with cCr protecting against spontaneous and chemically-induced convulsions in  CrT−/y mice. The 
only possible side effect could be the gain of alpha power during the sleep phase observed following the treatment 
with the 140 mg/kg cCr dose, potentially related to sleep  disturbances35,36. This is in contrast to a recent toxicol-
ogy study where cCr has been described to increase seizure incidence and brain vacuolation in Sprague–Dawley 
 rats37. This difference could be related to the higher doses used in the latter study (vacuolation was observed 
at 600 mg/kg/day), the different species (rats vs. mice) and/or the genotype of animals (wild type vs. animals 
lacking CrT function). Since cCr does not require CrT for cellular uptake, but can be transported by  CrT38, this 
could potentially lead to differential build-up of cCr in wild-type compared to  CrT−/y animals. Taken together, 
these data raise the possibility that cCr could have adverse effects on brain circuitry when present in excess, but 
additional formal toxicology studies in different species would be needed to assess the safety window of this drug.
Overall, our findings support the therapeutic efficacy of cCr for treating CTD, laying the foundation for the 
design of intervention protocols for this molecule or other chemically modified, lipophilic compounds that could 
be readily translated to the bedside.
Methods
Animals. We employed male mice hemizygous for CrT exons 5–7 deletion  (CrT−/y) on a C57Bl/6J 
 background39, and their wild-type (WT;  CrT+/y) littermates. All experiments were carried out in accordance 
with the European Directive of 22 September 2010 (EU/63/2010) and were authorized by the Italian Ministry of 
Health (authorization number 259/2016-PR and 507/2018-PR).
Drug administration and design of efficacy study. Cyclocreatine (cCr) was dissolved in 1% low-fat 
chocolate milk. Dosing solutions were stored at 2–8 °C between use and fresh solutions were made weekly. CCr 
in 1% chocolate milk was shown to be stable for 3 weeks at room temperature, and solubility was determined to 
be 15 mg/mL. Animals were left untreated or presented daily with 1% low-fat chocolate milk (vehicle treatment, 
V) or a 1% low-fat chocolate milk-cCr cocktail (in a volume of 5 ml/kg). cCr was administered once daily at three 
different dose levels (140, 46 or 14 mg/kg) over the course of 24 weeks starting in mice at postnatal day (PND) 
21. Longitudinal IOS imaging was conducted at PND40, PND110 and PND180. After completion of each IOS 
recording, mice were rested for at least four days and then each animal was subjected to serial neurobehavioral 
assessments of cognitive and psychomotor functions (Y maze, Morris Water Maze, rotarod and self-grooming). 
While Y maze, MWM and rotarod were longitudinally administered to the same animals, self-grooming was 
tested only at PND195 (see Fig. 1a). At the end of the dosing period (PND200), animals were monitored via EEG 
for 24 h and then challenged with KA. A subset of randomly selected M-CrT−/y (n = 5) and L-CrT−/y mice (n = 4) 
were not used for EEG and the brain was harvested for cCr pharmacokinetic profiling Otherwise, all animals 
were subjected to the same tests in the same time intervals with no differences in the experimental timeline was 
introduced between individuals or groups.
Intrinsic optical signal (IOS) imaging. Surgery and imaging sessions were performed as previously 
 described40. Images were visualized using a custom-made setup based on a Leica macroscope (Leica Z6 APO). 
Animals were fixed under the objective using a magnet mounted on an arduino-based imaging chamber. Red 
light illumination (630 nm) was obtained with 8 individually addressable LEDs (WS2812) secured to the objec-
tive (Leica PanApo 2.0X 10447170) by a custom 3D printed  holder41. Visual stimuli were generated using Mat-
lab Psychtoolbox and displayed on a screen placed 13 cm away from the eyes of the animals. Sinusoidal wave 
gratings were presented in the binocular portion of the visual field with spatial frequency 0.03 cyc/deg, mean 
luminance 20 cd/m2 and contrast 90%. The stimulus consisted in the abrupt contrast reversal of a grating with a 
temporal frequency of 4 Hz for 1 s. Frames were acquired at 30 fps with a 512 × 512 pixels resolution. The signal 
was averaged for at least 80 trials. Changes in reflectance (R) for each pixel were computed as the normalized 
difference from the average baseline (ΔR/R). A region of interest (ROI) was identified on the mean image of 
contralateral eye response by selecting the pixels in the lowest 30% ΔR/R of the range between the maximal and 
minimal pixel intensity, and mean evoked response was estimated as the average intensity within the ROI.  See40 
for further details on signal analysis.
Behavioral tests. All behavioral tests were performed as previously  reported11. Y-maze—We used a 
Y-shaped maze with three symmetrical plastic arms at a 120° angle (26 × 10 × 15  cm). Mice were allowed to 
explore the maze for 8 min. Video recordings (Noldus Ethovision XT) were employed for offline blind analysis. 
An arm entry was scored when all four limbs of the animal were within the arm. A triad was defined as a set 
of three consecutive arm entries, with each entry being into a different arm of the maze. The number of arm 
entries and the number of triads were recorded in order to calculate the alternation percentage. Morris water 
maze—Mice were trained for four trials per day and for a total of 7 days in a circular water tank (diameter, 
120 cm; height, 40 cm), filled to a depth of 25 cm with water (21–22 °C) added with non-toxic white paint. 
Four alternative starting positions defined the division of the tank into four quadrants. A square clear Perspex 
platform (11 × 11 cm) was submerged 0.5 cm below the water surface and located at the midpoint of the target 
quadrant. Mice were allowed up to 60 s to climb the escape platform, while their swimming paths were recorded 
by the Noldus Ethovision system. On the last trial (probe trial), the platform was removed and the swimming 
paths were recorded over 60 s. Rotarod—Mice were placed on an increasingly rotating drum (speed varying 
from 4 to 40 rpm in 10 min). The time spent on the drum was recorded by an automated unit. Four consecu-
tive trials with an inter-trial interval of 5 min were performed in a single day. Self-grooming—Each mouse was 
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placed individually into an empty, standard mouse cage (27 length, 20 cm wide, 15 cm high). Animal behavior 
was recorded for 20 min. After a 10-min habituation period, each mouse was scored for 10 min for cumulative 
time spent grooming all body regions.
EEG recordings. A two-channel headmount was placed on the skull of mice. EEG electrodes were stainless 
steel screws implanted epidurally over the frontal and the occipital areas. EEG signals were recorded using a pre-
amplifier connected to a data acquisition system and Sirenia Software 1.7.9 (Pinnacle Technology). Signals were 
recorded at 400 Hz sampling frequency to evaluate baseline (spontaneous) activity for 24 h followed by treat-
ment with i.p. kainic acid (KA) at 10 mg/kg to evoke seizure activity. Video was recorded in parallel during the 
entire duration of the EEG assessments. The vigilance state of the animals was classified as active wake, passive 
wake or sleep according to the video inspection. Signals were segmented in epochs lasting 30 s and converted 
into power spectra by Fast Fourier Transform: 0.5–4 (delta), 4–8 (theta), 8–12 (alpha), 12–30 (beta), and 30–45 
(gamma) Hz bands were analyzed. At least 12 epochs in each light/dark cycle and wake/sleep condition were 
averaged. To quantify both spontaneous and KA-evoked seizure episodes we used Sirenia Seizure Pro 1.8.4. The 
baseline period of each animal was used as a cutoff threshold (mean line length + 8 × SD). Events in the 2–10 Hz 
frequency range, with a line length higher than the defined threshold, and lasting at least 10 s were identified as 
seizures. At the behavioral level, seizures were scored according to Racine  scale42. Seizures of stage 1 and 2 were 
classified as tonic events, seizures of stage 3 were assigned to clonic events and seizures of stage 4, 5 and 6 were 
categorized as tonic–clonic events.
Satellite pharmacokinetic and histology study. Satellite mice were dosed in the same manner as the 
efficacy study animals and used for brain pharmacokinetics (PK) and histology evaluation.  CrT−/y mice were 
either not dosed  (CrT−/y) or treated daily with 1% low-fat chocolate milk (vehicle, V-CrT−/y) or 140 mg/kg cCr 
(H-CrT−/y). Of the 21 animals, 7 per group were terminated at each time point (PND44, PND114, or PND184). 
Twenty-four hours after the last dose, brains were harvested from the mice following whole-body perfusion 
with cold saline. One hemisphere was immediately snap frozen for PK study and the other hemisphere was 
fixed in 10% neutral-buffered formalin for histology. For PK, LC–MS/MS assays for cCr (limit of quantification 
0.35 nmol/g brain) and phospho-cCr (limit of quantification 0.22 nmol/g brain) were developed and used to 
measure concentrations of total cCr (summation of cCr and phospho-cCr) against an internal standard (cyclo-
creatine-1,4,5-13C3) in the brain hemispheres of all satellite H-CrT−/y animals at PND44, 114, and 184. Addition-
ally, brain PK was measured in 4–5 randomly selected M-CrT−/y and L-CrT−/y animals from the efficacy study at 
PND195 (after whole body perfusion with saline, see “Drug administration and design of efficacy study” para-
graph). For reference, brain creatine and phospho-creatine values in wild-type C57BL/6J mice were obtained 
in a separate study from the same laboratory that developed and ran the cCr/phospho-cCr assays. The mean 
total creatine value reported (12,813 nmol/g brain) is very similar to that reported by other groups in wild-type 
 animals10,11,43. For histology, 5 of the 7 animals in each group were randomly selected for evaluation at PND114 
and PND184. Hemispheres were trimmed into 8–10 coronal sections, embedded in paraffin, sectioned using 
a 5-micron block advance, and stained with Hematoxylin and Eosin. Amygdaloid body, basal nuclei/striatum, 
cerebellum, cerebral cortex, hippocampus, hypothalamus, medulla oblongata, meninges, midbrain, olfactory 
bulb, pons, thalamus ventricular system, and white matter were evaluated for each animal.
Statistical analysis. We estimated the sample size needed by performing a power analysis using G * Power 
(α = 0.05, β = 0.2). The estimate of the expected difference between the experimental groups was based on the 
knowledge of values of the studied parameter obtained historically in our laboratory in  CrT−/y animals. We 
estimated the minimal difference that would be biologically relevant considering the impact of the possible 
difference on the animals’ brain function and behavior. Since we performed a longitudinal study with differ-
ent measurements carried out in the same animals, we based the a priori statistical analysis on the parameter 
with the smallest effect size in previous experiments (Morris Water Maze). Starting from the hypothesis that 
cCr treatment would be effective in ameliorating the endophenotype of  CrT−/y mice, we established behavioral 
assessments as primary readouts, whereas IOS imaging, EEG recordings, PK measurements and histology were 
used as secondary readouts. All statistical analyses were performed using GraphPad Prism 8.0.1. The significance 
of factorial effects and differences among more than two groups were evaluated with ANOVA/RM ANOVA 
followed by post hoc Dunnett multiple comparison test. Fisher’s exact test and χ2 test were used to compare 
sampling distributions. A mixed-effects analysis was carried out for statistical evaluation of body weight. Rank 
transformation was exploited for data not normally distributed. The level of significance was p < 0.05.
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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